Therefore, PRMT1 inhibitors may exert their therapeutic effects in controlling tumor migration by inhibiting the EMT process, and changes in biomarkers and/or functions related to TGF-β/SMAD-mediated EMT can reflect the responses of tumor cells to PRMT1 inhibitors to a certain extent (Katsuno et al., 2018; Wei et al., 2019). Here, PRMT1 is linked to neoplasm.